The positive clinical data presented by Sutro Biopharma for Luvelta suggests a high potential for successful further development and approval, which is likely to be viewed favorably by investors. The high remission rates in a specific patient subgroup could position Luvelta as a significant treatment option, potentially leading to increased investor confidence and a positive short-term impact on STRO's stock price.